History
Fulhold Pharma was incorporated in February 2014.
The company's shares were admitted for trading on the GXG Market on 14 April 2015. Trading was suspended on 3 June 2015 at a price of 1.40 GBP and a market capitalisation of $108.9 million. According to financial media group, MoneyWeb, the trading suspension was due to "fallout from the investigations into companies with links to Belvedere Management." A June 2015 article in BizNews described the company as one of "four dubious British shell companies." Shareholders include founding director David Cosgrove, who resigned in March 2015, as well as Dualstar Capital Private Equity Fund and the Alexander High Yield Fund.
In August 2015, the company acquired Ful Hold Limited which had worked on a topical drug for wounds with Euprotec in 2013.
Products
Fulhold Pharma is a British pharmaceutical company with its manufacturing plant located in South Africa. It manufactures carbohydrate derived fulvic acid as an ingredient in medications.
Administration
A 2015 company press release listed David Squire as chief executive officer and chairman and Stephen Leivers as founder and chief scientific officer.